Intraperitoneal interferon-α in residual ovarian carcinoma: A phase II gynecologic oncology group study

Gynecologic Oncology

Volumn 75, Issue 1, 1999, Pages 10-14

  Berek, Jonathan S ^a   Markman, Maurie ^b   Stonebraker, Bette ^c   Lentz, Samuel S ^d   Adelson, Mark D ^e   DeGeest, Koen ^f   Moore, David ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LAPAROTOMY; LEUKOPENIA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; NEUTROPENIA; OVARY CARCINOMA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032878097     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5532     Document Type: Article

References (18)

1. Berek J S. Epithelial Ovarian Cancer. Berek J S, Hacker N F. Practical Gynecologic Oncology. 1994;340-366 Williams & Wilkins, Baltimore.
2. Myers C. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol. 11:1984;275-284.
3. Dedrick R, Myers C, Bungay P, DeVita V T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 62:1978;1-11.
4. Howell S, Pfeifle C, Wung W, Olshen R A, Lucas W E, Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 97:1982;845-851.
5. Pretorius G, Hacker N F, Berek J S, Ford L C, Hoeschele J D, Butler T A, Lagasse L D. The pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 67:1983;1085-1092.
6. Berek J S. Intraperitoneal adoptive immunotherapy for peritoneal cancer. J Clin Oncol. 10:1990;1610-1612.
7. Alberts D S, Liu P Y, Hannigan E V, O'Toole R, Williams S D, Young J A, Franklin E W, Clarke-Pearson D L, Malviya V K, DuBeshter B, Adelson M D, Hoskins W J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1997;1950-1955.
8. Epstein L B, Shen J T, Abele J S. Sensitivity of human ovarian carcinoma cells to IFN and other antitumor agents as assessed by an in vitro semi-solid agar technique. Ann N Y Acad Sci. 350:1980;228-235.
9. Einhorn N, Cantell K, Einhorn S, Stander H. Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol. 5:1982;167-172.
10. Freedman R S, Gutterman J T, Rutledge F N. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Modif. 2:1983;133-138.
11. Berek J S, Hacker N F, Lichtenstein A. Intraperitoneal recombinant alpha-interferon for a salvage immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res. 45:1985;4447-4453.
12. Willemse P HB, de Vries E GE, Mulder N H. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer. Eur J Clin Oncol. 26:1991;353-358.
13. Nardi M, Cognetti F, Pollera C F. Intraperitoneal recombinant alpha 2-interferon alternating with cisplatin as salvage therapy for minimal residual disease ovarian cancer: a Phase II study. J Clin Oncol. 8:1991;1036-1041.
14. Berek J S, Welander C, Schink J C. A Phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol. 40:1991;237-243.
15. Markman M, Berek J S, Blessing J A. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group Phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol. 45:1992;3-8.
16. Method M W, Braunstein R H, Averette H E. Intraperitoneal chemotherapy: technical considerations for catheter placement. J Gynecol Tech. 3:1997;385-394.
17. Blessing J A. Design, Analysis, and Interpretation of Chemotherapy Trials in Gynecologic Cancer. Deppe G. Chemotherapy of Gynecologic Cancer. 1984;49-83 A. R. Liss, New York.
18. Berek J S. Intraperitoneal immunotherapy for ovarian cancer with alpha interferon. Eur J Cancer. 28A:1992;719-721.